Therapy options in deep sternal wound infection: Sternal plating versus muscle flap

Martin Grapow¹, Martin Haug², Christopher Tschung¹, Bernhard Winkler¹,³*, Prerana Banerjee¹, Paul Philipp Heinisch³, Jens Fassl³, Oliver Reuthebuch¹, Friedrich Eckstein¹

¹ Department of Cardiac Surgery, University Hospital, Basel, Switzerland, ² Department of Plastic, Reconstructive, Aesthetic, and Hand Surgery, University Hospital, Basel, Switzerland, ³ Department of Cardiovascular Surgery, Inselspital, University Hospital, Bern, Switzerland

* publications.medic@gmail.com

Abstract

Background
Management of deep sternal wound infection (DSWI) in cardiac surgical patients still remains challenging. A variety of treatment strategies has been described. Aim of this cohort study was to analyse two different treatment strategies for DSWI: titanium sternal plating system (TSFS) and muscle flap coverage (MFC).

Methods
Between January 2007 and December 2011, from 3122 patients undergoing cardiac surgery 42 were identified with DSWI and treated with one of the above mentioned strategies. In-hospital data were collected, follow-up performed by telephone and assessment of Quality of Life (QoL) using the SF-12 Health Survey Questionnaire.

Results
20 patients with deep sternal wound infection were stabilized with TSFS and 22 patients treated with MFC. Preoperative demographics and risk factors did not reveal any significant differences. Patients treated with TSFS had a significantly shorter operation time (p<0.05) and shorter hospitalization (p<0.05). A tendency towards lower mortality rate (p = n.s.) and less re-interventions were also noted (plating 0.6 vs. flap 1.17 per patient, n.s.). Quality of Life in the TSFS group for the physical-summary-score was significantly elevated compared to the MFC group (p<0.05). Relating to chest stability and cosmetic result the treatment with TSFS showed superior results, but the usage of MFC gave the patients more freedom in breathing and less chest pain.

Conclusion
Our results demonstrate that the use of TSFS is a feasible and safe alternative in DSWI. However, MFC remains an absolutely essential option for complicated DSWI since the amount of perfused tissue can be the key for infection control.
Introduction

Conventional medium sternotomy is the most common access to the heart and mediastinum for cardiac surgeons since Julian et al. re-introduced Milton’s operation for this access in 1957 [1]. Deep Sternal Wound Infection (DSWI) with sternal dehiscence after cardiac surgery is nowadays a rare but highly feared complication associated with considerable morbidity and mortality [2]. Longer duration of hospitalization, expansive antibiotic treatments, reinterventions and significantly increased costs to healthcare systems are relevant consequences [3–7]. Several authors have reported about 16 up to 30 additional hospital days compared to patients with uncomplicated postoperative courses [8–11]. Upton et al. showed an up to 2-fold increase of cost per patient [6], Lee et al. described an additional cost of $ 500'000 per incident of post-sternotomy mediastinitis [5].

A variety of treatment concepts like extended debridement, open dressing-changes with secondary wound healing, Robiscek-wire closure, irrigation-suction drainage, closed drainage with multiple redon catheters at high negative pressure and others have been introduced in the past [12–19], but failure rates remained high. Thorough debridement, culture-directed antibiotics and the use of vacuum-assisted therapy (VAC) significantly decreased mortality and morbidity and is nowadays standard as first-line intervention for DSWI [12].

The transposition of a vascularized muscle flap as final therapy is considered to be the gold standard due to its tremendous potential of infection control. Application of a pectoralis major muscle flap coverage (MFC) in this setting was first described by Jurkiewics in the 80’s [20]. Several authors considered using MFC as the primary choice for wound closure in poststernotomy mediastinitis [15–17,21,22]. Besides the pectoralis major muscle flap a lot of different techniques like advancement, rotational or turnover flaps but also tissue sources such as rectus abdominis, latissimus dorsi muscle, and omentum plombing have been described in the reconstruction of dehiscent, infected sternotomy sites [21–23].

In 2005 Cicilioni et al. introduced sternal reconstruction with a transverse titanium sternal plating system (TSFS) in conjunction with a bilateral pectoralis advancement flap in DSWI [24]. The promising results were in line with later observations supporting this method as an alternative treatment option in the setting of infection, sternal dehiscence [25,26].

However, a general lack of consensus regarding the optimal treatment regimens and reconstructive techniques for this complication still exists [27]. The aim of this study was to perform a retrospective analysis in comparing both treatment, TSFS vs. MFC for the treatment of post-cardia DSWI, with special focus on Quality of Life and outcome to respect the most valid therapy suitable for this specific patients’ cohort.

Methods

Patient collective

Our retrospective analysis included all patients presenting with post-sternotomy DSWI, who underwent either sternal plating or muscular flap reconstruction from January 2007 to December 2011. An observational design was used in this analysis, conforming to the STROBE statement and checklist [28]. From a total of 3122 patients undergoing cardiac surgical operations with sternotomy at our institution. Overall 73 (2.27%) patients were identified having DSWI and of those 42 (1.35%) patients were treated exclusively with either TSFS or MFC. In this patient collective, the initially received cardiac procedures are listed in S1 Table. After diagnosis of DSWI and its pathogen all patients in both groups received wound preconditioning using VAC-therapy and antibiotics (100%) [29,30]. The most common isolated pathogen (S2 Table) was coagulase-negative staphylococcus in 50% of the cases (n = 24), staphylococcus...
Sternal plating versus muscle flap in DSWI

Aureus in 15% (n = 7) and enterobacteriaceae in 8% (n = 4). There were two cases of methicillin-resistant Staphylococcus aureus (MRSA). Additional information is provided in S2 Table.

A total of 20 patients received a stabilization with TSFS (15 males and 5 females). Furthermore, 22 patients (15 males and 7 females) were treated by MFC (Fig 1): rectus abdominis muscle-musculocutaneous flap (n = 9), pectoralis major muscular-musculocutaneous flap (n = 11), perforator flap (n = 1) and rectus abdominis—pectoralis major muscle—musculocutaneous flap (n = 1). The choice was made according to the surgeons preference and experience with the techniques.

The remaining 31 patients were treated with direct closure or the combination of VAC with delayed closure using wires in standard-fashion or the Robiscek-approach and were not part of our investigation.

Therefore, the cohort in this study represents a limited selection/population, containing patients with poor bone quality, failed first attempt or even resected sternum. The database was generated from patient charts of the University Hospital Basel, Switzerland.

Definition criteria

The definition of DSWI is according to the guidelines of the Centres for Disease Control and Prevention [31]: The definition of DSWI requires the presence of at least one of the following criteria: 1) an organism isolated from culture of mediastinal tissue or fluid; 2) evidence of mediastinitis seen during operation; or 3) presence of either chest pain, sternal instability, or fever (>38°C), and either purulent discharge from the mediastinum, isolation of an organism present in a blood culture, or culture of drainage of the mediastinal area.

After diagnosis of DSWI and its pathogen all patients in both groups received wound preconditioning using VAC-therapy and i.v. antibiotics (100%) until the mediastinum was properly cleaned and macroscopically without any signs of infection [29,30].

SF-12 questionnaire

The local ethics committee of the university hospital Basel approved this study. Written informed consent was obtained from all participating patients prior to the intervention and for a Quality of Life assessment with the standardized SF-12 Quality of Life Questionnaire Interview Form (Hogrefe Webedition). The physical and mental health sum scales were
computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Both physical and mental sum scores were computed that they compare a national norm score to have means of 50.0 and a standard deviations of 10.0 [32].

Besides the standardized SF-12 Quality of Life Questionnaire, six specific questions were included. Frequency of chest pain, constricted/captivated feeling and problems in breathing were asked, with four possible answers: from 1 to 4, score 1 indicates the highest level and 4 indicates the lowest level of having problems. Satisfactory of chest stability and cosmetic result were analyzed: score 1 indicates the lowest and 4 the highest level of satisfactory. The feeling of foreign body was asked, 1 for "yes" and 0 for "no". All patients were contacted and interviewed by phone. For better viewing and understanding purposes the answers have been transformed in percentages: 0%, 33%, 66%, 100%.

**Statistical analysis**

The SF-12 questionnaire is a 12-item short health survey for self-administration as well as scripts for personal interviews. We used the standard version for telephone interview provided by Hogrefe Testsystem (Hogrefe Publishing Corp.) which was completed by our questionnaire focused on relevant questions. Continuous variables were expressed as mean with standard deviation, median and range, whereas categorical data were expressed as percentages.

For continuous variables, values were compared using the Mann Whitney U-Test. Differences in proportion were compared using Fisher’s exact test. A p value of less than 0.05 was considered statistically significant. All statistical analysis was performed using IBM SPSS Statistics 20 for Windows.

**Results**

**Demographic data**

Preoperative patient characteristics revealed no significant differences, although patients receiving a MFC presented with an increased EuroScore, which was mainly driven by a reduced left ventricular ejection fraction (LVEF) and a frequent history of myocardial infarction (Table 1). Patients undergoing TSFS had a higher body mass index (BMI) and a more frequent history of cerebral vascular insult (CVI).

**Time period between cardiac surgery and final closure**

Postoperative data analyses revealed significantly more first attempts of operative sternal re-stabilization in the MFC group (86.6% vs. 35.0%, p = 0.001). Statistically significant differences were also found in the number of VAC-dressing changes before final treatment for sternal dehiscence (MFC 3.7±1.2 versus 2.7±1.5 per patient, p = 0.012). A tendency towards longer ICU stays with a mean of 14.2 days versus 7.5 days and more resuscitation in the MFS group with 36.36% compared to only 15% in the TSFS group were evident, although being not significant (Table 2).

**Final closure and further course**

Operation time for TSFS was significantly shorter compared to MFC (138.8±25.8 h vs. 184.3±75.9 h; p = 0.009) the postoperative ICU stay was comparable, the period from final reconstruction to hospital discharge was significantly shorter in the TSFS group (18.1±20.6 d vs. 38.9±39.3 d; p = 0.025).
Though statistically not significant, patients treated with TSFS had a tendency towards fewer secondary operative interventions (bleeding, seroma, necrosis, recurrent infection, hardware removal) after final reconstruction (0.6 ± 1.1 vs. 1.2 ± 1.9 per patient, p = 0.24) and a lower mortality rate (Table 3). In the TSFS group sternal plates were removed in one case due to seroma formation four months after surgery. There was no sign of infection and due to sternal stability the plates could be removed without an alternative stabilization.

Table 1. Preoperative patient characteristics for each treatment group.

|                          | TSFS (n = 20) | MFC (n = 22) | p Value |
|--------------------------|---------------|--------------|---------|
| Age at Operation         | 70.5 (40–83), 70±9.7 | 73 (54–84), 70.8±8.5 | 0.74    |
| Male Gender              | 15 (75.0)     | 15 (68)      | 0.74    |
| EuroScore additive       | 7 (3–12), 7.8±2.9 | 8 (5–15), 8.8±2.9 | 0.32    |
| EuroScore logistic       | 7.04 (2.56–29.92), 12.0±9.0 | 9.78 (3.44–52.25), 14.9±12.8 | 0.32    |
| LVEF, %                  | 59 (30–89), 53.4±15.7 | 50 (20–80), 48.4±16.9 | 0.39    |
| Body Mass Index, kg/m2   | 31.5 (25–50), 33.7±7.6 | 31 (20–44), 30.6±6.3 | 0.23    |
| Diabetes mellitus        | 12 (45.0)     | 11 (50.00)   | 0.77    |
| Chronic Obstructive Pulmonary Disease | 5 (25.0) | 2 (9.09) | 0.23 |
| Hypertension             | 16 (80.0)     | 20 (90.91)   | 0.40    |
| Peripheral Vascular Disease | 4 (20.0) | 3 (13.64) | 0.69    |
| Active smoker or stopped <3 months | 3 (15.0) | 3 (13.64) | 1.00    |
| Steroids                 | 2 (10.0)      | 1 (4.55)     | 0.60    |
| HO Stroke/Transient Ischemic Attack | 6 (25.0) | 1 (4.55) | 0.087   |
| HO Myocardial Infarction | 9 (45.0)      | 17 (77.27)   | 0.055   |
| Osteoporosis             | 2 (10.0)      | 2 (9.09)     | 1.00    |
| Re-Do surgery            | 0 (0.00)      | 2 (9.09)     | 0.49    |

Data are presented as Median and Range with Mean ± standard deviation or absolute value and percentage (%). HO = History of. LVEF = Left ventricular ejection fraction

https://doi.org/10.1371/journal.pone.0180024.t001

Though statistically not significant, patients treated with TSFS had a tendency towards fewer secondary operative interventions (bleeding, seroma, necrosis, recurrent infection, hardware removal) after final reconstruction (0.6 ± 1.1 vs. 1.2±1.9 per patient, p = 0.24) and a lower mortality rate (Table 3). In the TSFS group sternal plates were removed in one case due to seroma formation four months after surgery. There was no sign of infection and due to sternal stability the plates could be removed without an alternative stabilization.

Table 2. Intra- and postoperative patient data.

|                          | TSFS (n = 20) | MFC (n = 22) | p       |
|--------------------------|---------------|--------------|---------|
| Postoperative ICU Stay (d) | 4.5 (2–27), 7.5±7.3 | 5 (2–69), 14.2±18.4 | 0.22    |
| Cardiac Operation Time (min) | 214.5 (134–462), 232.4±70.2 | 268 (115–415), 258.7±75.5 | 0.10    |
| Emergency Operation      | 6 (30.0)      | 2 (9.09)     | 0.12    |
| Pneumonia                | 12 (60.0)     | 11 (50.00)   | 0.55    |
| Post-OP Delir            | 14 (70.0)     | 10 (45.45)   | 0.13    |
| DSWI                     | 20 (100)      | 22 (100.00)  | 1.00    |
| Post-OP Bleeding         | 2 (10.0)      | 2 (22.73)    | 0.41    |
| Seroma Formation         | 7 (35.0)      | 6 (27.27)    | 0.35    |
| Tracheotomy              | 1 (0.05)      | 4 (18.18)    | 0.19    |
| VAC usage in n patients  | 20 (100)      | 22 (100.00)  | 1.00    |
| Number of VAC changes    | 3 (1–6), 2.7±1.5 | 4 (1–6), 3.7±1.2 | 0.012   |
| Sternum Revision         | 7 (35.0)      | 19 (86.36)   | 0.001   |
| Resuscitation            | 3 (15.0)      | 8 (36.36)    | 0.166   |

Data are presented as Median and Range with Mean ± standard deviation or absolute value and percentage (%). ICU = Intensive care unit. VAC = Vacuum-assisted closure

https://doi.org/10.1371/journal.pone.0180024.t002
Thirty-day mortality was 9.5%, 1-year mortality was 21.4% and total all-cause mortality after a mean follow-up of 33.42 months was 28.3% for the entire cohort. Overall mortality for the TSFS-group was 10% for 30 days, 15% for 1 year and 15% with a mean follow-up of 34.6 months. The MFC-group showed a 30-day mortality of 9.0%, 27% and 40% with a mean follow-up of 23.6 months. Six patients died in the MFC group, and three patients in the TSFS group within one year after final reconstruction, most of them due to multi organ failure (S3 Table).

**SF-12 questionnaire**

In the TSFS group, 14 patients agreed to answer the SF-12 Quality of Life questionnaire in a 4 weeks range: 1 patient left the country and was lost to follow-up. Two patients got TSFS explanted at time of follow up and 3 patients died during time of follow-up. Only 8 Patients agreed to answer the questionnaire in the MCF group: Two patients were lost to follow-up. Another patient suffered from severe dementia and was unable to answer the questionnaire. In total 9 patients have died during the follow-up period, six patients within 1 year and 3 more patients beyond 1 year after final surgery. Two patients did not agree to participate.

The standardized SF-12 questionnaire compared two aspects in quality of life on the Norm Scale Calculator, the physical sum scale revealed a statistically significant better physical quality of life for patients in the TSFS group (42.8±8.6 vs. 29.5±10.7 p = 0.034), (Fig 2) and (Table 4). The mental sum scale was similar between the groups. Further information regarding preoperative and postoperative patient characteristics for each treatment group in the SF12 questionnaire are presented in S4 and S5 Tables.

**Specific questionnaire**

For those six additional questions no significant differences were obtained (Fig 3). Chest pain was seen more frequently in TSFS patients and satisfaction with the cosmetic result combined with the sensation of a stable chest was less likely in MFC patients. Specific patient data after definite therapy in SF-12 group are presented in S6 Table.
Fig 2. Results of the SF-12 questionnaire.
https://doi.org/10.1371/journal.pone.0180024.g002

Table 4. SF-12 questionnaire-results.

|                      | TSFS (n = 14)                           | MFC (n = 8)                             | p-value |
|----------------------|----------------------------------------|-----------------------------------------|---------|
| Physical Sum Scale   | 44.7 (27.7–56.2), 42.8±8.6             | 32.7 (21.6–48.8), 29.5±10.7             | 0.034   |
| Mental Sum Scale     | 56.2 (29.0–64.1), 51.4±11.1             | 47.8 (24.7–64.8), 49.9±13.2±13.2        | 0.375   |

Data are presented as Median and Range, Mean± standard deviation. P Value has been calculated by Mann-Whitney U test.

https://doi.org/10.1371/journal.pone.0180024.t004

Fig 3. Specific questionnaire.
https://doi.org/10.1371/journal.pone.0180024.g003
Discussion

The application of a transverse titanium sternal plating system was first described by Cicilioni et al. in 2005 [24]. Since then evidence has accumulated that the approach of using titanium plate osteosynthesis in a preconditioned and preserved sternal surrounding offered by modern VAC therapy has the potential to become an alternative in the therapy of complex DSWI [12,16,26]. The goal of this study was to analyse the effect of different treatment options in DSWI, TSFS vs. MFC, on quality of life and outcome.

Despite numerous advancements in perioperative care, 30-day mortality was 9.5%, 1-year-mortality was 21.4% and total all-cause-mortality after a mean follow-up of 33.42 months was 28.3% for the entire cohort. The results are comparable to the data published by Milano et al [33] analysing long-term outcome of CABG-patients with mediastinitis, a mortality of 28.6% was demonstrated at 1.5 years. Another study by the Leipzig group shows an in-hospital-mortality of 21.6%. In this study in-hospital-mortality was significantly lower (17.1%) in patients undergoing isolated CABG, but increased in patients undergoing other procedures (43.5%) [34]. Our patients underwent in 64.2% isolated CABG, the remaining 35.8% combination surgery.

Although the preoperative demographic data were almost similar between the groups, they differed in a few but important aspects after cardiac surgery. A tendency towards longer ICU stays and more resuscitation in the MFS group were evident, although being not significant. However, secondary closure attempts (after initial cardiac operation) with wires have been performed significantly more often in the MFC group in 86.36% versus 35% in the TSFS group. Gummert et al. reported increased hospital mortality in patients requiring more than one operation to treat the infection [34]. Furthermore, VAC-dressing changes were carried out significantly more often for MFC patients as compared to TSFS patients.

This again had major impact on the time interval cardiac-surgery-to-final-sternal-reconstruction, which was consecutively delayed for the MFC cohort. One possible explaining factor is the patient-referral to our Division of Plastic and Reconstructive Surgery accompanied by a prolonged operative planning period, whereas TSFS patients were scheduled and operated by cardiac surgeons. Karra et al. conducted a multivariate analysis of risk factors for 1-year mortality after postoperative mediastinitis. The group concluded that a delay in sternal closure to be a major highly significant independent predictor with a hazard ratio of 6.27 [35]. In contrast to a large 15-year review by Baillot et al. who reported a decreased perioperative mortality treated with VAC followed by TSFS in 92 patients compared with muscle flaps [12].

In the current study 30-day mortality was almost identical between the groups in our cohort. There was only a tendency towards an increased long-term mortality. Patients treated with TSFS were better by trend with a total all-cause-mortality of 15% after a mean follow-up of 3 years compared to 40.9% after a mean follow-up of 25.9 months. Patients supplied with TSFS were discharged significantly earlier, while time of intubation and time on ICU were similar between the groups. Although statistically not significant operative interventions due to postoperative bleeding, seroma formation, recurrent infection, resection of necrotic tissue or hardware removal were performed by trend less often in the TSFS group. This again might reflect the different health condition in both groups before final sternal treatment. All over 5 out of 20 patients had to be reoperated in our cohort which is similar to the data published by Schols et al. [16]. They presented their results in 22 patients, who were supplied by sternal plates and pectoralis major advancement flaps, too. Although 15 patients showed an uneventful postoperative course, 7 patients complained about fistulas and wound dehiscence, 4 of them presented with a recurrence of infection.
To our knowledge this is the first analysis in which outcome and QoL are directly compared between patients treated with the TSFS and MFC. Our results of the SF-12 Quality of Life Questionnaire concerning the physical summary scale show, that patients treated with the TSFS have a significantly better quality of life (p = 0.03).

Interestingly the physical situation did not affect the psychological status, i.e. the mental summary scale, which did not reveal any relevant differences.

Plass et al. investigated preoperative and postoperative pulmonary function test on 41 patients treated with the TSFS in their study. All of the patients showed no worsening in respiratory function [26]. In our questionnaire only 2 of 14 (14%) patients complained of “often” having problems in breathing, 5 of 14 (36%) “sometimes”. Whereas in the MFC group 1 of 8 (13%) complained of “often”, and 4 of 8 (50%) “sometimes” having problems in breathing. Patients with a TSFS reported more often about pain, but on the other hand they were more satisfied with the cosmetic result and with the achieved stability of the chest. There was no significant difference found on the results of the questionnaire.

We acknowledge some limitations of our study. Due to the low incidence of DSWI the number of investigated patients in our study is small. Patients included were operated in a five-year-period between 2007 to 2011 in order to have a similar spectrum of indication, therapeutic options and of course a reasonable number of patients. Another limitation is that this study is a retrospective analysis. Although demographic data for both patient groups were similar before cardiac surgery both groups developed differently in the period between cardiac surgery and final sternal stabilization in favour of the TSFS group. Best evidence is guaranteed by performing a prospective randomized controlled multi-center study.

The evaluation of the SF-12 Quality of Life questionnaire has also to be done with caution, since the problem of confounding factors cannot totally be ruled out. The questionnaire is a subjective test and does not provide hard facts.

Several advantages are assumed for TSFS compared to MFC closure with proposed early postoperative extubation, decreased sternal pain, improved comfort, decreased mediastinal hernia and paradoxical chest wall breathing [25,26]. The results demonstrate, that the use of TSFS is a potential and safe option in DSWI with respect to the limitations of this study.

Besides less complication, shorter hospital stays and lower mortality rate. In the long-term follow-up a better quality of life on the physical norm scale was found. However, MFC remains an absolutely essential therapy option for complicated DSWI since the amount of perfused tissue can be the key for infection control. Nevertheless, the usage of TSFS should be evaluated for every patient. Through the use of the TSFS the anatomical, biomechanical and physiological function of the chest is maintained, furthermore it is the less invasive therapy option.

Supporting information

S1 Table. Cardiac procedures.
(DOCX)

S2 Table. Isolated pathogens from wound cultures.
(DOCX)

S3 Table. Cause of death and 1-year mortality.
(DOCX)

S4 Table. Preoperative patient characteristics for each treatment group in SF12 group.
(DOCX)
S5 Table. Intra- and postoperative patient data in SF-12 group.

S6 Table. Patient data after definite therapy in SF-12 group.

Author Contributions
Conceptualization: OR FE MG.
Data curation: MH CT.
Formal analysis: OR FE MG CT BW MH.
Funding acquisition: OR FE MG.
Investigation: MH CT MG.
Methodology: OR FE MG MH.
Project administration: MG OR FE MH JF.
Resources: JF OR FE MG.
Software: MG MH CT.
Supervision: MG OR FE JF.
Validation: OR FE MG PB JF BW.
Visualization: OR FE MG PPH JF BW.
Writing – original draft: FE OR MG CT BW.
Writing – review & editing: BW PPH OR FE MG CT JF.

References
1. Dalton ML, Connally SR, Sealy WC. Julian's reintroduction of Milton's operation. vol. 53. 1992.
2. Braxton JH, Marrin CAS, McGrath PD, Morton JR, Norotsky M, Charlesworth DC, et al. 10-year follow-up of patients with and without mediastinitis. Semin Thorac Cardiovasc Surg 2004; 16:70–6. PMID: 15366690
3. Mauermann WJ, Sampathkumar P, Thompson RL. Sternal wound infections. Best Pract Res Clin Anaesthesiol 2008; 22:423–36. PMID: 18331296
4. Ariyaratnam P, Bland M, Loubani M. Risk factors and mortality associated with deep sternal wound infections following coronary bypass surgery with or without concomitant procedures in a UK population: a basis for a new risk model? Interact Cardiovasc Thorac Surg 2010; 11:543–6. https://doi.org/10.1510/icvts.2010.237883 PMID: 20739410
5. Lee JC, Raman J, Song DH. Primary sternal closure with titanium plate fixation: plastic surgery effecting a paradigm shift. Plast Reconstr Surg 2010; 125:1720–4. https://doi.org/10.1097/PRS.0b013e3181d51292 PMID: 20517097
6. Upton A, Smith P, Roberts S. Excess cost associated with Staphylococcus aureus poststernotomy mediastinitis. N Z Med J 2005; 118:U1316. PMID: 15776092
7. Singh K, Anderson E, Harper JG. Overview and management of sternal wound infection. Semin Plast Surg 2011; 25:25–33. https://doi.org/10.1055/s-0031-1275168 PMID: 22299400
8. Floros P, Sawhney R, Vrtik M, Hinton-Bayre A, Weimers P, Senewiratne S, et al. Risk factors and management approach for deep sternal wound infection after cardiac surgery at a tertiary medical centre. Heart Lung Circ 2011; 20:712–7. https://doi.org/10.1016/j.hlc.2011.08.001 PMID: 21906999
9. Bitkover CY, Gårdlund B. Mediastinitis after cardiovascular operations: a case-control study of risk factors. Ats 1998; 65:36–40.
10. Centofanti P, Savia F, La Torre M, Ceresa F, Sansone F, Veglio V, et al. A prospective study of prevalence of 60-days postoperative wound infections after cardiac surgery. An updated risk factor analysis. J Cardiovasc Surg (Torino) 2007; 48:641–6.

11. Jonkers D, Elenbaas T, Terponten P, Nieman F, Stobberingh E. Prevalence of 90-days postoperative wound infections after cardiac surgery. European Journal of Cardio-Thoracic Surgery 2003; 23:97–102. PMID: 12493512

12. Baillot R, Cloutier D, Montalin L, Côté L, Lellouche F, Houde C, et al. Impact of deep sternal wound infection management with vacuum-assisted closure therapy followed by sternal osteosynthesis: a 15-year review of 23,499 sternotomies. Eur J Cardiothorac Surg 2010; 37:880–7. https://doi.org/10.1016/j.ejcts.2009.09.023 PMID: 19880326

13. Gaudreau G, Costache V, Houde C, Cloutier D, Montalin L, Voisine P, et al. Recurrent sternal infection following treatment with negative pressure wound therapy and titanium transverse plate fixation. Eur J Cardiothorac Surg 2010; 37:888–92. https://doi.org/10.1016/j.ejcts.2009.07.043 PMID: 19775906

14. Robicsek F, Daugherty HK, Cook JW. The prevention and treatment of sternal separation following open-heart surgery. J Thorac Cardiovasc Surg 1977; 73:267–8. PMID: 319304

15. Ennker IC, Pietrowski D, Vöhringer L, Kojcici B, Albert A, Vogt PM, et al. Surgical debridement, vacuum therapy and pectoralis myocutaneous flap for sternal wound infection: a 15-year experience. Eur J Cardiothorac Surg 2011; 40:1467–72. https://doi.org/10.1093/ejcts/ezr275 PMID: 21846492

16. Schols RM, Lauwers TMAS, Geskes GG, van der Hulst RRWJ. Deep sternal wound infection after open heart surgery: Current treatment options. Eur J Cardiothorac Surg 2010; 37:888-6. https://doi.org/10.1016/j.ejcts.2009.07.043 PMID: 19775906

17. Gaudreau G, Costache V, Houde C, Cloutier D, Montalin L, Voisine P, et al. Recurrent sternal infection following treatment with negative pressure wound therapy and titanium transverse plate fixation. Eur J Cardiothorac Surg 2010; 37:888–92. https://doi.org/10.1016/j.ejcts.2009.07.043 PMID: 19775906

18. van Wingerden JJ, Lapid O, Boonstra PW, de Mol BAJM. Muscle flaps or omental flap in the management of deep sternal wound infection. Interact Cardiovasc Thorac Surg 2011; 13:487–92. https://doi.org/10.1093/icvts/ivq105 PMID: 22162911

19. Jones G, Jurkiewicz MJ, Bostwick J, Wood R, Bried JT, Culbertson J, et al. Management of the infected median sternotomy wound with muscle flaps. The Emory 20-year experience. Ann Surg 1997; 225:766–76–discussion776–8.

20. van Wingerden JJ, Lapid O, Boonstra PW, de Mol BAJM. Muscle flaps or omental flap in the management of deep sternal wound infection. Interact Cardiovasc Thorac Surg 2011; 13:487–92. https://doi.org/10.1093/icvts/ivq105 PMID: 22162911

21. Cowan KN, Teague L, Sue SC, Mahoney JL. Vacuum-assisted wound closure of deep sternal infections in high-risk patients after cardiac surgery. Ann Thorac Surg 2005; 80:2205–12. https://doi.org/10.1016/j.athoracsur.2005.04.005 PMID: 16308572

22. Jurkiewicz MJ, B J III, HESTER TR, BISHOP JB, CRAVER J. Infected Median Sternotomy Wound Successful Treatment by Muscle Flaps. Ann Surg 1980; 191:738–44. https://doi.org/10.1097/00000658-198006000-00012 PMID: 7387236

23. Hallock GG. The pectoralis major muscle extended island flap for complete obliteration of the median sternotomy wound. Ann Plast Surg 2007; 59:655–8. https://doi.org/10.1097/SAP.0b013e318049e6d5 PMID: 18046148

24. Graeber GM. Chest wall resection and reconstruction. Semin Thorac Cardiovasc Surg 1999; 11:251–63. PMID: 10451257

25. Li EN, Goldberg NH, Slezak S, Silverman RP. Split Pectoralis Major Flaps for Mediastinal Wound Coverage. Ann Plast Surg 2004; 53:334–7. https://doi.org/10.1097/00000658-200006000-00012 PMID: 15385766

26. Cicilioni OJ, Stieg FH, Papanicolaou G. Sternal wound reconstruction with transverse plate fixation. Plast Reconstr Surg 2005; 115:1297–303. PMID: 15809589

27. Fawzy H, Osei-Tutu K, Errett L, Latter D, Bonneau D, Musgrave M, et al. Sternal plate closure for sternal wound dehiscence: initial experience (retrospective study). J Cardiothorac Surg 2011; 6:63. https://doi.org/10.1186/1749-8090-6-63 PMID: 21529357

28. Bastuji-Garin S, Sbidian E, Gaudy-Marqueste C, Ferrat E, Roujeau J-C, Richard M-A, et al. Impact of PROBE Statement Publication on Quality of Observational Study Reporting: Interrupted Time Series versus Before-After Analysis. PLoS ONE 2013; 8:e64733. https://doi.org/10.1371/journal.pone.0064733 PMID: 23990867

29. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999; 27:97–132–quiz133–4–discussion96.
30. Raja SG, Berg GA. Should vacuum-assisted closure therapy be routinely used for management of deep sternal wound infection after cardiac surgery? Interact Cardiovasc Thorac Surg 2007; 6:523–7. https://doi.org/10.1510/icvts.2007.157370 PMID: 17669926

31. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128–40. https://doi.org/10.1016/0196-6553(88)90053-3 PMID: 2841893

32. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220–33. PMID: 8628042

33. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 1995; 92:2245–51. https://doi.org/10.1161/01.CIR.92.8.2245 PMID: 7554208

34. Gummer JF, Barten MJ, Hans C, Kluge M, Doll N, Walther T, et al. Mediastinitis and cardiac surgery—an updated risk factor analysis in 10,373 consecutive adult patients. Thorac Cardiovasc Surg 2002; 50:87–91. https://doi.org/10.1055/s-2002-26691 PMID: 11981708

35. Karra R, McDermott L, Connelly S, Smith P, Sexton DJ, Kaye KS. Risk factors for 1-year mortality after postoperative mediastinitis. J Thorac Cardiovasc Surg 2006; 132:537–43. https://doi.org/10.1016/j.jtcvs.2006.04.037 PMID: 16935107